申请人:——
公开号:US20030199508A1
公开(公告)日:2003-10-23
Compounds of formula I:
1
[wherein:
X represents —CH═CH—, —CH═CR—, —CR═CR—, —CO—, —O—, —NH—, —NR—, S—, —SO—, —SO
2
—, —CH═N—, —CR═N—, —CH═N(O)—, —CR═N(O)— or any other atom or group of atoms capable of forming a S— or 6-membered heterocyclic ring;
Y
1
, Y
2
and Y
3
independently represent hydrogen or halogen;
R
1
, R
2
and R
3
are independently represent hydrogen, halogen, hydrocarbyl (—R), hydroxyl (—OH), hydrocarbyloxy (—O—R), mercapto (—SH), hydrocarbylthio (—S—R), hydrocarbylsulfinyl (—SO—R), hydrocarbylsulfonyl (—SO
2
—R), nitro (—NO
2
), amino (—NH
2
), hydrocarbylamino (—NHR), bis(hydrocarbyl)amino (—NR
2
), hydrocarbylcarbonylamino (—NH—CO—R), cyano (—CN), carbamoyl (—CONH
2
), hydrocarbylcarbarnoyl (—CONHR), bis(hydrocarbyl)carbamoyl (—CONR
2
), carboxyl (—CO
2
H), hydrocarbyloxycarbonyl (—CO
2
R), formyl (—CHO), hydrocarbylcarbonyl (—COR), hydrocarbylcarbonyloxy (—OCOR), optionally substituted heteroaryl or optionally substituted heterocyclic; and
the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R1, R2 and R3]; are of use in the manufacture of a medicament for the treatment including prophylaxis of disease mediated by the activation of GSK-3.
公式I的化合物:其中:X代表—CH₂CH—、—CH₂CR—、—CR₂CR—、—CO—、—O—、—NH—、—NR—、S—、—SO—、—SO₂—、—CH₂N—、—CR₂N—、—CH₂N(O)—、—CR₂N(O)—或任何其他能够形成S—或6元杂环的原子或原子团;Y₁、Y₂和Y₃独立地代表氢或卤素;R₁、R₂和R₃独立地代表氢、卤素、烃基(—R)、羟基(—OH)、烃氧基(—O—R)、巯基(—SH)、烃硫基(—S—R)、烃基磺基(—SO—R)、烃基磺酰基(—SO₂—R)、硝基(—NO₂)、氨基(—NH₂)、烃基氨基(—NHR)、双(烃基)氨基(—NR₂)、烃基羰基氨基(—NH—CO—R)、氰基(—CN)、氨基甲酰基(—CONH₂)、烃基甲酰胺基(—CONHR)、双(烃基)氨基甲酰基(—CONR₂)、羧基(—CO₂H)、烃氧羰基(—CO₂R)、甲酰基(—CHO)、烃基羰基(—COR)、烃基羰氧基(—OCOR)、可选地取代的杂芳烃或可选地取代的杂环;烃基R为直链或支链烃基,选自烷基、烯基、炔基、芳基、芳基烷基、芳基烯基和芳基炔基,该基团可以选择地被一个或多个取代基取代,所述取代基选自与R₁、R₂和R₃相关定义的那些取代基;用于制造一种药物,用于治疗包括预防GSK-3激活介导的疾病的药物。